Publications et communications

PRINCIPALES PUBLICATIONS DES DERNIÈRES ANNÉES

2024

André N, Deley MCL, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P, Entz-Werlé N, Leblond P. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors. Eur J Cancer. 2024 Jan 6;198:113525.

2023

Allory Y, Culine S, Krucker C, Fontugne J, Harter V, Pfister C. Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. J Urol. 2023 Dec 28:101097JU0000000000003836. doi: 10.1097/JU.0000000000003836. Online ahead of print.

Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2023 Dec 21:S1470-2045(23)00587-9.

Divoux J, Florent R, Jacobs M, Lequesne J, Grellard JM, San C, Grossi S, Kerdja K, Clarisse B, Boudier G, Cherifi F, Briand M, Dolivet E, Johnson A, Dubois B, Harter V, Lacroix J, Raboutet C, Marie B, Rousseau N, Blanc-Fournier C, Vaur D, Figeac M, Poulain L, Weiswald LB, Emile G. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer. BMC Cancer. 2023 Sep 19;23(1):883.

Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study. BMC Cancer. 2023 Aug 9;23(1):736.

Penel N, Bonvalot S, Le Deley MC, Italiano A, Tlemsani C, Pannier D, Leguillette C, Kurtz JE, Toulmonde M, Thery J, Orbach D, Dubray-Longeras P, Verret B, Bertucci F, Guillemet C, Laroche L, Dufresne A, Blay JY, Le Cesne A. Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value. Int J Cancer. 2023 Jul 15;153(2):407-416.

Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials. Acta Oncol. 2023 Jul;62(7):744-752.

Culine S, Harter V, Krucker C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Fontugne J, Allory Y, Pfister C; VESPER Trial Investigators. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers (Basel). 2023 Mar 13;15(6):1742.

Perréard M, Florent R, Divoux J, Grellard JM, Lequesne J, Briand M, Clarisse B, Rousseau N, Lebreton E, Dubois B, Harter V, Lasne-Cardon A, Drouet J, Johnson A, Le Page AL, Bazille C, Jeanne C, Figeac M, Goardon N, Vaur D, Micault E, Humbert M, Thariat J, Babin E, Poulain L, Weiswald LB, Bastit V. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer. 2023 Mar 9;23(1):223.
 

2022

Leman R, Parfait B, Vidaud D, Girodon E, Pacot L, Le Gac G, Ka C, Ferec C, Fichou Y, Quesnelle C, Aucouturier C, Muller E, Vaur D, Castera L, Boulouard F, Ricou A, Tubeuf H, Soukarieh O, Gaildrat P, Riant F, Guillaud-Bataille M, Caputo SM, Caux-Moncoutier V, Boutry-Kryza N, Bonnet-Dorion F, Schultz I, Rossing M, Quenez O, Goldenberg L, Harter V, Parsons MT, Spurdle AB, Frébourg T, Martins A, Houdayer C, Krieger S. SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing. Hum Mutat. 2022 Dec;43(12):2308-2323

Tran TV, Rubino C, Allodji R, Andruccioli M, Bardet S, Diallo I, Dottorini M, Garsi J, Hall P, Henry-Amar M, Lamart S, Le Thai F, Lönn S, Ricard M, Schvartz C, Schlumberger M, Journy N, de Vathaire F. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022 Dec;127(12):2118-2124

Coquan E, Clarisse B, Lequesne J, Brachet PE, Nevière Z, Meriaux E, Bonnet I, Castera M, Goardon N, Boutrois J, Travers R, Joly F, Grellard JM, Thiery-Vuillemin A. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma. BMC Cancer. 2022 Nov 24;22(1):1213

Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials. J Cancer Surviv. 2022 Nov 28. Online ahead of print.

Pfister C, Harter V, Allory Y, Culine S; VESPER Trial Investigators. Reply to S. Zeng et al.  J Clin Oncol. 2022 Sep 10;40(26):3094-3095.

Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulié M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20;40(18):2013-2022

Neviere Z, Coquan E, Brachet PE, Meriaux E, Bonnet I, Krieger S, Castéra L, Vaur D, Boulouard F, Leconte A, Lequesne J, Lelaidier A, Ricou A, Joly F. Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations. Curr Oncol. 2022 Apr 15;29(4):2776-2791

Nerich V, Guyeux C, Henry-Amar M, Couturier R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas R-O, Morschhauser F, Feugier P, Sibon D, Ysebaert L, Nicolas-Virelizier E, Broussais-Guillaumot F, Damaj GL, Jais J-P, Salles G, Woronoff-Lemsi M, Mounier N. Economic Burden in Non-Hodgkin Lymphoma Survivors: The French Lymphoma Study Association SIMONAL Cross-Sectional Study. Cancer. 2022 Feb 1;128(3):519-528
 

2021

Gernier F, Ahmed-Lecheheb D, Pautier P, Floquet A, Nadeau C, Frank S, Alexandre J, Selle F, Berton-Rigaud D, Kalbacher E, Orfeuvre H, Lortholary A, Augereau P, Labombarda F, Perrier L, Grellard JM, Licaj I, Clarisse B, Savoye AM, Bourien H, De La Motte Rouge T, Kurtz JE, Kerdja K, Lelaidier A, Charreton A, Ray-Coquard I, Joly F. Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors. BMC Cancer. 2021 Oct 26;21(1):1147

Binarelli G, Lange M, Dos Santos M, Grellard J-M, Lelaidier A, Tron L, Lefevre arbogast S, Clarisse B, Joly F. Multimodal web-based intervention for cancer-related cognitive impairment in breast cancer patients: Cog-Stim feasibility study protocol. Cancers. Cancers (Basel). 2021 Sep 28;13(19):4868

Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Di Fiore F, Roubaud G, Barthélémy P, Voog E , Emambux S , Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard J-C, Huillard O , Rolland F, Houédé N, Spano J-P, El Demery M, Vieillot S, L’Haridon T, Hilgers W, Allory Y, Pfister C, for the VESPER Trial Investigators. Chemotherapy for muscle-invasive bladder cancer: impact of cisplatin delivery on renal function and local control rate in the randomized phase III VESPER (GETUG-AFU V05) trial. Clin Genitourin Cancer. 2021 Sep 8:S1558-7673(21)00162-2

Coquan E, Brachet PE, Licaj I, Leconte A, Castera M, Lequesne J, Meriaux E, Bonnet I, Lelaidier A, Clarisse B, Joly F. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. BMC Cancer. 2021 Sep 25;21(1):1054

Joly F, Rigal O, Guittet L, Lefèvre-Arbogast S, Grellard J-M, Binarelli G, Lange M,  Rieux C, Fernette M, Tron L, Gernier F, Travers R, Morel A, Richard D, Griffon G,  Leconte A, Bastien  E, Quilan F, Pépin L-F, Jardin F, Leheurteur M, Clarisse B, Lequesne J, Faveyrial A. Post-traumatic stress symptomatology and adjustment of medical oncology practice during the COVID-19 pandemic among adult patients with cancer in a day care hospital. Cancer. 2021 Aug 16:10.1002/cncr.33856

Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol. 2021 Feb;79(2):214-221

Xiao D, Guizard A-V, Daubisse-Marliac L, Woronoff A-S, Trétarre B, Delafosse P, Molinié F, Cowppli-Bony A, Lapôtre-Ledoux B, Bara S, Marrer E, Velten M, Laroche L, Heutte N, Grosclaude P, Joly F. Evaluation of long-term living conditions in patients treated for localised prostate cancer. Eur J Cancer Care (Engl). 2021 Jan;30(1):e13333

2020

Pfister C, Gravis G, Flechon A, Soulie M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S. Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique. Prog Urol. 2020 Nov;30(13):715-716

Culine S, Gravis G, Flechon A, Soulie M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Pfister C. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses. Journal of Clinical Oncology. 2020 Feb;38(6_suppl):437-437

Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar.

Leman R, Harter V, Atkinson A, Davy G, Rousselin A, Muller E, Castéra L, Lemoine F, de la Grange P, Guillaud-Bataille M, Vaur D, Krieger S. SpliceLauncher: a tool for detection, annotation and relative quantification of alternative junctions from RNAseq data. 2020 Mar 1;36(5):1634-1636.

Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Eur J Cancer. 2020 Feb;126:45-55

2019

Busson R, van der Kaaij M, Mounier N, Aleman BMP, Thiéblemont C, Stamatoullas A, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Kluin-Nelemans HC, Henry-Amar M. Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. Health Qual Life Outcomes. 2019 Jul 2;17(1):115

Dos Santos M, Lequesne J, Dugué AE, Grellard JM, Ory C, Jaffré S, Lavergne K, Lelaidier A, Laroche L, Divanon F, Delcambre C, Galais MP, Clarisse B, Faveyrial A. Optimisation of chemotherapy prescription and preparation in an ambulatory unit: Validation of the OPTIMA program. Eur J Cancer Care (Engl). 2019 May;28(3):e13015

Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, Salles G, Henry-Amar M. Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2019 Mar 22

Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019 Mar 4;19(1):198

2018

Castéra L, Harter V, Muller E, Krieger S, Goardon N, Ricou A, Rousselin A, Paimparay G, Legros A, Bruet O, Quesnelle C, Domin F, San C, Brault B, Fouillet R, Abadie C, Béra O, Berthet P; French Exome Project Consortium, Frébourg T, Vaur D. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med. 2018 Dec;20(12):1677-1686

Thomas J, Fermé C, Noordijk E, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145

Mariette C, Renaud F, Piessen G, Gele P, Copin MC, Leteurtre E, , Delaeter C, , Dib M, Clisant S, Harter V, Bonnetain F, Duhamel A, Christophe V, Adenis A and Fregat Working Group. The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers. BMC Cancer. 2018 Feb 6;18(1):139

2017

Renaud F, Bibeau F, Leteurtre E, Delaeter C, Dib M, Harter V, Adenis A, Piessen G, Mariette C; FREGAT working group. FREGAT: French clinico-biological database dedicated to esogastric cancers. Ann Pathol. 2017 Dec;37(6):457-466.

Davy G, Rousselin A, Goardon N, Castéra L, Harter V, Legros A, Muller E, Fouillet R, Brault B, Smirnova AS, Lemoine F, de la Grange P, Guillaud-Bataille M, Caux-Moncoutier V, Houdayer C, Bonnet F, Blanc-Fournier C, Gaildrat P, Frebourg T, Martins A, Vaur D, Krieger S. Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer. Eur J Hum Genet. 2017 Oct;25(10):1147-1154.

Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial. Int J Radiat Oncol Biol Phys. 2017 Oct 27. pii: S0360-3016(17)33984-6.

Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017 Oct;102(10):1748-1757.

Petry S, Sévin C, Fleury MA, Duquesne F, Foucher N, Laugier C, Henry-Amar M, Tapprest J. Differential distribution of vapA-positive Rhodococcus equi in affected and unaffected horse-breeding farms. Vet Rec. 2017 Aug 5;181(6):145.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer. 2017 Aug;81:45-55.

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N. Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment Bull Cancer. 2017 Mar;104(3):221-231

2016

Henry-Amar M, Busson R. Does persistent fatigue in survivors relate to cancer? Lancet Oncol. 2016 Oct;17(10):1351-1352

Debeaumont D, Tardif C, Folope V, Castres I, Lemaitre F, Tourny C, Dechelotte P, Thill C, Darmon A, Coquart JB. A specific prediction equation is necessary to estimate peak oxygen uptake in obese patients with metabolic syndrome. J Endocrinol Invest. 2016 Jun;39(6):635-42

Oldrini G, Harter V, Witte Y, Martrille L, Blum A. Age Estimation in Living Adults using 3D Volume Rendered CT Images of the Sternal Plastron and Lower Chest. Journal of Forensic Sciences. 2016 Jan;61(1):127-33

2015

Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015 Nov;2(11):e492-502

Durand I, Deverriere G, Thill C, Lety AS, Parrod C, David N, Barre E, Hazelzet T. Prenatal Detection of Coarctation of the Aorta in a Non-selected Population: A Prospective Analysis of 10 Years of Experience. Pediatr Cardiol. 2015 Aug;36(6):1248-54

Loschi M, Thill C, Gray C, David M, Bagatha MF, Chamseddine A, Contentin N, Jardin F, Lanic H, Lemasle E, Lenain P, Stamatoullas A, Tilly H, Lepretre S. Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients. Mycopathologia. 2015 Jun;179(5-6):337-45

Yaribakht S, Guillemin F, Harter V, Malartic C, Marchal F. New approach of learning curve for robotic-assisted gynecologic oncology surgery. Gynecol Obstet Fertil. 2015 May;43(5):348-55

Raft J, Guerci P, Harter V, Fuchs-Buder T, Meistelman C. Biological evaluation of the effect of sugammadex on hemostasis and bleeding. Korean J Anesthesiol. 2015 Feb;68(1):17-21

2014

Boyrie S, Charra-Brunaud C, Harter V, Ducassou A, Kirova Y, Barillot I, Krzisch C, Lang P, Baron MH, Montbarbon X, Delannes M, Peiffert D. Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancer. Brachytherapy. 2014 Jul-Aug;13(4):326-31

Petry S, Sévin C, Fleury MA, Duquesne F, Foucher N, Laugier C, Henry-Amar M, Tapprest J. Distribution of virulent Rhodococcus equi and its virulence plasmid types in environment from horse-breeding farms with and without a history of R. equi pneumonia in Normandy (France). Res Vet Sc. 2014 (short communication, in press)

Haddad A, Peiffert D, Lapeyre M, Harter V, Buchheit I, Graff P. A case-control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapy. Brachytherapy. 2014 Jun 6. pii: S1538-4721(14)00538-8

Renoult F, Marchal C, Brunaud C, Harter V, Peiffert D. Safety and efficacy of whole breast irradiation with a concomitant boost: Analysis of 121 cases treated at the institut de cancérologie de Lorraine. Cancer Radiother. 2014 Jun;18(3):165-70

Huger S, Graff P, Harter V, Marchesi V, Royer P, Diaz JC, Aouadi S, Wolf D, Peiffert D, Noel A. Evaluation of the Block Matching deformable registration algorithm in the field of head-and-neck adaptive radiotherapy. Phys Med. 2014 May;30(3):301-8

Rebstock LE, Leufflen L, Leroux A, Harter V, Verhaeghe JL, Marchal F. Granulosa cell tumor of the ovary: Retrospective study of 17 cases. Gynecol Obstet Fertil. 2014 May;42(5):331-3

van der Kaaij MA, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Eghbali H, Brice P, Smit WG, Sebban C, Doorduijn JK, Roesink JM, Gaillard I, Coiffier B, Lybeert ML, Casasnovas O, André M, Raemaekers JM, Henry-Amar M, Kluin-Nelemans JC; for the European Organisation for Research and Treatment of Cancer Lymphoma Group and the Groupe d’Étude des Lymphomes de l'Adulte. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Hum Reprod. 2014 Mar;29(3):525-33

2013

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group : […] Henry-Amar M […]. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013 Jun;14(7):619-26

Harlé A, Busser B, Rouyer M, Harter V, Genin P, Leroux A, Merlin JL. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch. 2013 Mar;462(3):329-35

Harlé A, Lion M, Lozano N, Husson M, Harter V, Genin P, Merlin JL. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncol Rep. 2013 Mar;29(3):1043-52

Chretien AS, Harlé A, Meyer-Lefebvre M, Rouyer M, Husson M, Ramacci C, Harter V, Genin P, Leroux A, Merlin JL. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. Cancer Med. 2013 Feb;2(1):11-20

2012

Mallet E, Gaudelus J, Reinert P, Stagnara J, Bénichou J, Castanet M, Thill C, Basuyau JP, Billard C, Roden A, Uhlrich J. Prophylactic prescription of vitamin D in France: national multicenter epidemiological study of 3240 children under 6 years of age. Arch Pediatr. 2012 Dec;19(12):1293-302.

van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser LC, Allgeier A, Meulemans B, Dubois B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Doorduijn JK, Sebban C, Smit WG, Bologna S, Roesink JM, Ong F, André MP, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol. 2012 Nov 1;30(31):3854-63

Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C, Castelain B, Thomas L, Peiffert D. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol. 2012 Jun;103(3):305-13

Renard-Oldrini S, Brunaud C, Huger S, Marchesi V, Tournier-Rangeard L, Bouzid D, Harter V, Peiffert D. Dosimetric comparison between the intensity modulated radiotherapy with fixed field and Rapid Arc of cervix cancer. Cancer Radiother. 2012 May;16(3):209-14

van der Kaaij MAE, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AHM, Lugtenburg PJ, Aleman BMP, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Bologna S, Ong F, Eghbali H, Doorduijn JK, Morschhauser F, Sebban C, Roesink JM, Bouteloup M, van Hoof A, Raemaekers JMM, Henry-Amar M, Kluin-Nelemans HC. Premature ovarian failure and fertility in long-term survivors of Hodgkin lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’Étude des Lymphomes de l’Adulte cohort study. J Clin Oncol 2012;30:291-299.

2011

Noal S, Levy C, Hardouin A, Rieux C, Heutte N, Segura C, Collet F, Allouache D, Switsers O, Delcambre C, Delozier T, Henry-Amar M, Joly F. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2011;81(3):795-803.

Klein D, Mercier M, Abeilard E, Puyraveau M, Danzon A, Dalstein V, Pozet A, Guizard AV, Henry-Amar M, Velten M. Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Res Treat 2011;129(1):125-134.

Caravati-Jouvenceaux A, Launoy G, Klein D, Henry-Amar M, Abeilard E, Danzon A, Pozet A, Velten M, Mercier M. Health-related quality of life among long-term survivors of colorectal cancer: a population-based study. Oncologist 2011;16(11):1626-1636

Tapprest J, Laugier C, Sevin C, Foucher N, Duquesne F, Henry-Amar M. Pulmonary rhodococcosis in foals: risk factors related to horse husbandry in France. Revue Méd Vét 2011;162(12):563-573

Lheureux S, Clarisse B, Launay-Vacher V, Gunzer K, Delcambre-Lair C, Bouhier-Leporrier K, Kaluzinski L, Maron D, Ngo MD, Grossi S, Dubois B, Zalcman G, Joly F. Evaluation of current practice: management of chemotherapy-related toxicities. Anticancer Drugs 2011;22(9):919-925.

Clin B, Morlais F, Launoy G, Guizard AV, Dubois B, Bouvier V, Desoubeaux N, Marquignon MF, Raffaelli C, Paris C, Galateau-Salle F, Guittet L, Letourneux M. Cancer incidence within a cohort occupationally exposed to asbestos: a study of dose--response relationships. Occup Environ Med 2011;68(11):832-836.

2010

Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, Bourgeois H. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol 2010;116(3):312-316

Fritschi L, Guenel P, Ahrens W; European Study Group on Occupational Causes of Rare Cancers. Breast cancer in priests: follow-up of an observation made 167 years ago. Eur J Epidemiol 2010;25(3):219-221

2009

Clin B, Morlais F, Dubois B, Guizard AV, Desoubeaux N, Marquignon MF, Raffaelli C, Paris C, Galateau-Salle F, Launoy G, Letourneux M. Occupational asbestos exposure and digestive cancers - a cohort study. Aliment Pharmacol Ther. 2009 Aug 15;30(4):364-74

Labiche A, Elie N, Herlin P, Denoux Y, Crouet H, Heutte N, Joly F, Héron JF, Gauduchon P, Henry-Amar M. Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histol Histopathol 2009;24(4):425-435

Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van't Veer MB, Aleman BM, Noordijk EM, Thomas J, Fermé C, Henry-Amar M; for the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Études des Lymphomes de l'Adulte (GELA). Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009;115(8):1680-1691

Aide N, Heutte N, Rame JP, Rousseau E, Henry-Amar M, Bardet S. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metabol 2009;94(6):2075-2784

Haas RL, Girinsky T, Aleman BM, Henry-Amar M, de Boer JP, de Jong D. Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2009;74(4):1199-1202

Garsi JP, Schlumberger M, Ricard M, Labbé M, Ceccarelli C, Schvartz C, Henry-Amar M, Bardet S, Rubino C, de Vathaire. Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clin Endocrinol 2009;71(6):880-883

Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M, Culine S. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 2009 Aug 1;7(2):E28-E33

Joly F, Petit T, Pautier P, Guardiola E, Mayer F, Chevalier-Place A, Delva R, Sevin E, Henry-Amar M, Bourgeois H. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study. Gynecol Oncol 2009;115(3):382-388

Heutte N, Flechtner HH, Mounier N, Mellink WAM, Meerwaldt JH, Eghbali H, van’t Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RWM, Smit WGJM, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomšič R, Feugier P, Salles G, Gabarre J, Kersten MJ, van den Neste E, Creemers GJM, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, for the EORTC-GELA H8 Trial. Quality of life after successful treatment of early-stage Hodgkin lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 2009;10:1160-1170

van der Kaaij MA, Heutte N, van Echten-Arends J, Raemaekers JM, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Brice P, Bonmati C, Henry-Amar M, Kluin-Nelemans HC. Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica 2009;94:1691-1697

2008

Béghin L, Castera M, Manios Y, Gilbert CC, Kersting M, De Henauw S, Kafatos A, Gottrand F, Molnar D, Sjöström M, Leclercq C, Widhalm K, Mesana MI, Moreno LA, Libersa C; HELENA Study Group. Quality assurance of ethical issues and regulatory aspects relating to good clinical practices in the HELENA Cross-Sectional Study. Int J Obes (Lond). 2008 Nov;32 Suppl 5:S12-8.

PRINCIPALES COMMUNICATIONS

J. Jenvrin-Breton, M.C. Grach, S. Jeandel, A. Gueguen, O.Rigal, A. Bencheman, C. Lefeuvre, F. Lebrun, E. Fortin, S. Vilet, L. Rosaert, J.M. Commer, F. Maucourt, S. Benoit, P. Bourrel, N. Lemoal, N. Lelievre, M. Blondel, A. Barrault, M. Henry-Amar, M.Y. Moreau, J.M. Grellard, B. Griffon, B. Clarisse, C. Thill. Soins de bouche et cancer: Prise en charge des patients identifiés soins palliatifs et hospitalisés.  Congrès de la Société Française d’Accompagnement et de soins Palliatifs, Lille, 2013 (communication affichée)

Lange M, Giffard B, Noal S, Heutte N, Daireaux A, Rieux C, Lévy C, Allouache D, Jouie L, Dubois B, Le Fel J, Roy V, Rigal O, Kurtz E, Eustache F, Joly F. Fonctionnement cognitif de patientes âgées traitées pour un cancer du sein localisé : évaluation pré-traitement adjuvant. 6èmes journées scientifiques du Cancéropôle Nord-Ouest. Deauville, 2013 (communication affichée)

Harter V, Mayeux M, Desandes E. Identitovigilance et détection de doublons au Centre Alexis Vautrin (CLCC de la région Lorraine). Congrés EMOIS, Nancy, 2013 (communication orale)

Harter V, Peiffert D, Levitchi M, Charra-Brunaud C, Desandes E. Détermination d’une dose-seuil prédictive de l’apparition de toxicités digestives et urinaires à partir de la vraisemblance du modèle de Cox chez des patientes traitées par curiethérapie PDR 3D pour uncarcinome du col de l’utérus. 6ème Conférence Francophone d'Épidémiologie Clinique - 19èmes Journées des Statisticiens des Centres de Lutte contre le Cancer. Lyon, 2012 (communication affichée)

van der Kaaij MAE, Heutte N, Meijnders P, Raemaekers JMM, Abeilard-Lemoisson E, Allgeier A, Meulemans B, Simons AHM, Mounier N, Henry-Amar M, Kluin-Nelemans JC. Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study. ASCO Annual Meeting. June 3-7, 2011; Chicago, USA. J Clin Oncol 2011;29:15s (Suppl; Abstr 9062) (communication affichée).

Dubray B, Beckendorf V, Guerif S, Le Prise E, Reynaud-Bougnoux A, Hannoun Levi JM, Nguyen TD, Hennequin C, Cretin J, Fayolle-Campana M, Lagrange JL, Bachaud JM, Azria D, Grangirard A, Pommier P, Simon JM, Harter V, Habibian M. Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer ? - Interim analysis of GETUG 14 randomized trial (EU-20503 / NCT00104741). ASCO Annual Meeting. June 3-7, 2011; Chicago, USA (communication affichée).

van der Kaaij MAE, Heutte N, Meijnders P, Raemaekers JMM, Abeilard-Lemoisson A, Allgeier A, Meulemans B, Simons AHM, Mounier N, Henry-Amar M, Kluin-Nelemans HC. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. 11th International Conference on Malignant Lymphoma (11-ICML). June 15-18, 2011; Lugano, Switzerland. Ann Oncol 2011;22(Suppl 4):iv139 (Abstr 165) (communication orale).

Dubois B, Laborde L. Role du datamanager dans le processus qualité. Eurocancer, John Libbey Eurotext, Paris, 2011, pp.299-300 (communication orale) 

OUVRAGES

Culine L, Belda-Mathieu E, Berneur-Morisseau C, Castéra-Tellier M, Demerville L. Mémento de la recherche biomédicale portant sur un médicament à usage humain. Springer Deuxième édition, 2011